Author

P. Schmid

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access 2026

TROFUSE-032: a phase 3, randomized study of pembrolizumab plus sacituzumab tirumotecan or chemotherapy followed by pembrolizumab plus chemotherapy for early-stage triple-negative breast cancer or hr+/her2– breast cancer

Introduction: Trophoblast cell surface antigen 2 (TROP2) is highly expressed in triple-negative breast cancer (TNBC) and is associated with poor prognosis. Current standard of care for high-risk, early-stage TNBC is neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab after surgery. The same a...

R. Freitas-Júnior, P. Schmid, Jing Wei et al. · Mastology · 0 citations

Review Oct 2026

Pembrolizumab Plus Chemotherapy for HR+/HER2- PD-L1‒Positive Advanced Breast Cancer: Final Analysis of the Phase 3 KEYNOTE-B49 Study.

BACKGROUND We evaluated pembrolizumab plus chemotherapy versus chemotherapy alone in participants with PD-L1‒positive, hormone receptor-positive (HR+)/HER2- advanced breast cancer after progression on prior endocrine-based therapy (ET). PATIENTS AND METHODS Participants with locally recurrent inoperable or metastatic...

H. Rugo, M. Kok, A. Gonçalves et al. · Annals of Oncology · 0 citations

Open access Oct 2026

TroFuse-032 study design: pembrolizumab plus sacituzumab tirumotecan or chemotherapy followed by pembrolizumab plus chemotherapy as neoadjuvant therapy for early-stage, triple-negative breast cancer or HR-low+/HER2- breast cancer.

CLINICAL TRIAL REGISTRATION NCT06966700 (ClinicalTrials.gov); EU CT 2024-520190-12 (EudraCT).

P. Schmid, Javier Cortés, R. Hui et al. · Future Oncology · 0 citations